Background: Deep brain stimulation (DBS) for the treatment of neurologic diseases has markedly increased in popularity over the past 15 years. This review primarily focuses on movement disorder applications and efficacy of DBS, but also briefly reviews other promising new and old uses of DBS. Review Summary: A multidisciplinary team consisting of a movement disorders neurologist, a functional neurosurgeon, and a neuropsychologist optimally selects patients for DBS. Patients must be significantly disabled despite optimal medical therapy and be cognitively healthy without significant psychiatric disorders. Although this surgery is elective, it should not be withheld until the patient suffers marked loss of quality of life. Patients must have support from caregivers and postoperatively multiple DBS programming visits may be required. DBS of the subthalamic nucleus (STN) and the globus pallidus pars interna (GPi) significantly improves motor performance, activities of daily living, and quality of life in advanced Parkinson disease. In addition, STN DBS allows for marked reductions of antiparkinson medication. Stimulation of the ventralis intermedius nucleus of the thalamus is an effective treatment for essential tremor with sustained long-term effects. The GPi may be the preferred site of stimulation for dystonia with movement scores typically improved by 75% in patients with primary dystonia. Conclusions: DBS is an effective surgical treatment for movement disorders with sustained long-term benefits. Further research is ongoing to better understand the mechanism of DBS, refine the hardware to improve efficacy and reduce adverse effects, and identify additional applications and new anatomic targets.
MECHANISM OF DBS
The mechanism of DBS is currently incompletely understood and may differ depending on the site of stimulation. The effects of DBS have been well documented to be frequency dependent, with the greatest relief of symptoms at Ͼ100 Hz and no therapeutic relief at Ͻ50 Hz. Stimulation pulse width determines which neural elements are preferentially affected; longer pulse widths influence the cell soma, whereas shorter pulse widths mainly affect axons. Furthermore, DBS results in highly localized stimulation because relatively low currents are used which result in small current spread (about 2-3 mm with an intensity of 2 mA) and the intensity of stimulation decreases proportionally to the square of the distance. 1, 2 It has been suggested that the mechanism is reversible inhibition of the target site because the results and effects are comparable to ablation. Ashby and Rothwell have proposed that thalamic DBS activates output neurons from specific thalamic nuclei to the reticular nucleus, which sends reciprocal inhibitory efferents back to specific thalamic nuclei. 3 Furthermore, several studies suggest that high-frequency stimulation increases the excitatory response from the implanted site. 4 -6 GPi stimulation may result in activation of GPe GABAergic axons that inhibit GPi neurons. 7 A similar phenomenon may exist with STN DBS. Two additional hypotheses have been proposed as the mechanism(s) of DBS: (1) depolarization blockade of myelinated axons (however, with DBS the stimulation rates used clinically are too low to create a depolarization blockade in animal models); (2) "neuronal jamming" whereby activation of fibers transfers nonphysiological and incomprehensible messages to downstream target nuclei, which are then disregarded. 8 It is likely that the neuroanatomical effects of DBS are complex incorporating a combination of various mechanisms.
The clinical effects of DBS disappear within seconds (Vim DBS for tremor) to hours (STN DBS for parkinsonian freezing of gait) upon discontinuation of stimulation. That some effects persist for hours after discontinuation suggests that downstream plastic changes are induced with chronic stimulation. Post mortem examination of patients who have undergone long-term DBS reveals minimal gliosis surrounding the stimulating electrode and moderate cell loss surrounding the tip of the electrode.
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DBS VERSUS LESIONING
The beneficial results of DBS and ablation are similar in terms of improvement of tremor and parkinsonism. However, DBS electrode implantation causes fewer permanent neurologic adverse effects compared with lesioning because much less brain tissue is destroyed. Radiofrequency lesions may be inadvertently expanded or be misplaced to involve important structures adjacent to the intended target. Bilateral stimulation can also be safely performed with a much lower risk of cognitive and bulbar adverse effects commonly seen with bilateral thalamic and pallidal lesioning. [12] [13] [14] [15] [16] With DBS, stimulation parameters can be finely adjusted to maximize beneficial results and minimize adverse effects caused by current spread to adjacent structures. DBS electrodes can also be surgically repositioned if they are initially suboptimally situated, and the hardware can be removed at anytime. In contrast, the effects of ablation are irreversible and not adjustable without additional surgery. Figure 1 displays the DBS hardware including the internal pulse generator (IPG), connection cables, and implanted quadripolar electrode. Ablation and electrode implantation are usually performed with the patient awake; however, DBS requires an additional surgery performed under general anesthesia to implant the IPG and connector wire, and the IPG needs to be surgically replaced every 2 to 7 years because of battery end of life. Several visits are typically necessary after electrode implantation to adjust the stimulation parameters, especially for patients undergoing GPi or STN DBS, and minimal follow-up is required after ablation. Approximately 25% to 30% of patients with DBS experience hardware complications that may even occur more than 1 year postoperatively, typically involving mechanical hardware breakage, or skin erosion over the hardware, which maybe associated with cutaneous infection. 17, 18 These complications usually require replacement of damaged or infected hardware and sometimes treatment with antibiotics. Furthermore, migration of the DBS electrode has been reported to rarely occur. 19 In patients with severe postural instability and frequent falls, ablative surgery may be preferred because falls may damage or displace DBS hardware. DBS is also a very expensive procedure compared with ablation; hence, in many areas of the world, lesioning procedures are the only affordable surgical option.
PATIENT SELECTION
The formation of a multidisciplinary team consisting of a movement disorders neurologist, a functional neurosurgeon, and a neuropsychologist helps to optimally select patients for surgery. The role of the neurologist is to ensure the correct diagnosis of the disease and that all appropriate nonsurgical treatments have been employed. The neurosurgeon evaluates the patient's general health with respect to the risks of surgery and frankly discusses with the patient the potential complications of surgery including a 1% to 2% chance of intracerebral hemorrhage per operated side, which could result in serious neurologic disability or death. The neuropsychologist performs an in depth cognitive examination to determine if there are any signs of dementia, and interviews the patient and caregiver to determine if there are behavioral abnormal-
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ities or psychiatric problems such as anxiety, substance abuse, depression, psychosis, or mania. Although, there are no firmly validated criteria to select patients for surgery, some common basic guidelines have been adopted by many surgical centers. In general, appropriate candidates for surgery have substantial disability in performance of activities of daily living (ADL) or tasks necessary for employment despite optimal drug therapy. Patients must have the mental and physical stamina to endure a lengthy and demanding procedure, and be cognitively healthy with low levels of anxiety to provide useful intraoperative feedback and assist with postoperative stimulation adjustments. Demented patients tend to become more confused intraoperatively, being unable to provide reliable reports of adverse effects during intraoperative stimulation, and it may be difficult to optimally program stimulation parameters because of their lack of insight into their own motor status. Many patients with essential tremor are elderly; hence, a full cognitive assessment should be performed if there are concerns regarding age-associated dementia. Furthermore, surgery can potentially worsen preexisting cognitive deficits in PD patients with features suggestive of early neurodegenerative dementia. 20 -24 However, cognitive impairments associated with PD or dystonia should not be considered exclusion criteria, but significant abnormalities not normally present in these neurologic diseases (such as impaired lexical and semantic verbal fluency) may be the basis for exclusion. 24, 25 Recommendations for screening, clinical and research evaluations of cognition and behavior have been published. 25 Additional contraindications include severe uncontrolled hypertension, cancer, or cardiac, renal, hepatic, or pulmonary diseases.
Determining the appropriate timing of surgery can sometimes be difficult because DBS is often elective and is undertaken to improve a patient's quality of life. The patient and the physician should frankly discuss the potential for significant improvement and adverse effects of more aggressive drug therapy compared with surgery. There are many factors that must be considered in this decision including the patient's personal, professional, and social situation. Regardless, surgery should not be unnecessarily delayed until the patient loses his or her job or there is a marked reduction in independence and loss of quality of life.
Patients must have realistic expectations of the beneficial effects that they may derive from DBS. Typically, we emphasize to PD patients that their best-on state preoperatively will not be improved, but that motor fluctuations, dyskinesias, and medication requirements will be reduced. This is reemphasized to the patient and the family at the time of the formal preoperative challenge test (see text below). To identify patients with unrealistic expectations, we also ask the patient and family to complete a brief questionnaire outlining their motor and psychologic expectations of surgery, and this is reviewed with the patient and family preoperatively by the neurologist and neuropsychologist.
Parkinson Disease
PD is characterized predominantly by loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) resulting in striatal dopamine deficiency. This is thought to result in hyperactivity of the indirect and underactivity of the direct basal ganglia pathways with increased inhibition of the thalamus consequently reducing motor cortex activity (Fig.  2) . The STN contains the only glutamatergic excitatory outputs in the basal ganglia and sends widespread projections to a large number of areas including to the GPi/substantia nigra pars reticulata (SNr), the main inhibitory outputs of the basal ganglia. Surgical interventions targeting the STN and GPi may alleviate parkinsonism by reducing the excessive inhibitory output of the basal ganglia. The Vim nucleus of the thalamus receives predominately cerebellar afferents and is believed to be an integral part of the multiple oscillating loops responsible for the generation of tremor. Surgical intervention may interrupt its rhythmic firing and reduce tremor.
We have observed that many patients who initially underwent Vim DBS for treatment of tremor have subsequently required GPi or STN surgery to treat other symptoms, such as bradykinesia, gait disorders, and levodopa-induced dyskinesias, which have become more pronounced with progression of PD. In our experience, STN DBS improves tremor as effectively as thalamic surgery; hence, we advocate GPi or STN surgery as the initial surgical procedure in patients with severe medication-refractory tremor-dominant PD and no longer recommend Vim DBS as a treatment for PD. 26, 27 Recently, some groups have begun to investigate stimulation of the pedunculopontine nucleus (PPN) for refractory gait disorders.
28 Table 1 lists the major criteria and predictors to be considered when selecting PD patients for surgery. Surgery should be considered for PD patients with medication-refractory motor fluctuations and levodopa-induced dyskinesias, disabling medication-refractory tremor, or marked medication intolerance making medical management unsatisfactory. In general, patients who do respond to levodopa should not be considered for surgery. Previous surgery for PD does not contraindicate additional surgery if the patient is otherwise an appropriate surgical candidate, although technically such surgery may be more difficult. There are reports of successful bilateral STN DBS performed in patients with prior unilateral thalamotomy, unilateral or bilateral thalamic DBS, unilateral pallidotomy, and unilateral or bilateral GPi DBS. 29 -33 Some groups exclude older patients (especially those older than 70 years) because in general this group benefits less compared with a younger population because of more levodopa-refractory disability (features of parkinsonism that are not improved with high doses of antiparkinson medication thought to be predominantly due to nondopaminergic degeneration) and a higher risk of cognitive deterioration with surgery. 21, 24 However, elderly patients with a very good levodopa response and who are otherwise healthy clearly demonstrate significant improvement. 22 Patients that hallucinate or develop other symptoms of psychosis with dopaminergic drugs are often demented or almost universally subsequently become demented within the next few years; hence, these patients should be generally excluded from surgery. 20, 25, 34 The Grenoble group excludes PD patients with a Mini-Mental Status Examination score Յ24/30 or with a Mattis Dementia Rating Scale score Յ130/144. 1 However, in highly select cases surgery might be considered for those with the combination of mild preoperative cognitive abnormalities and severe motor disability, where the potential for worsening cognition with surgery is outweighed by the possibility of improvement in motor disability and ADL. 35, 36 PD patients with poor on-period postural stability with frequent falls preoperatively should be considered candidates for surgery with some circumspection because they are at a higher risk of falls and injury because of reduced bradykinesia and a faster gait associated with improvements from DBS and as a result overall functional benefit with DBS may be limited. 22 Although a single report does not indicate any significant change in personal and socioprofessional adaptation behavior 2 years postoperative with STN DBS, it is still possible that there may be a transient, difficult adjustment period associated with the new role of the patient being less dependent on others due to marked improvement of symptoms. 37 Hence, patients must have emotional support available from family or other caregivers postoperatively. Caregivers must also aid patients in attending multiple DBS programming visits, especially PD patients who may need to attend clinic often after overnight drug withdrawal in a poorly mobile state.
The degree of improvement obtained with a supramaximal dose of levodopa (usually the first morning dose of antiparkinson medication with an additional 50 -100 mg of levodopa) after overnight withdrawal of antiparkinson medication is highly predictive of the response to STN DBS and probably also GPi DBS. 22, 33, 38, 39 Lentiform nucleus hypermetabolism on FDG-PET (positron emission tomography) scanning also correlates with the response to levodopa and pallidotomy and may correlate with the response to DBS. 40 Therefore, the levodopa test is an important part of the evaluation to determine the degree of benefit obtainable with surgery. With the exception of tremor, signs that are not improved with levodopa usually fail to improve with surgery and include cognitive and psychiatric problems, on-period freezing, and levodopa-refractory dysarthria, dysphagia, and postural instability. 22, 41 Furthermore, the levodopa test reinforces for the patient and family realistic expectations of the potential maximal results of surgery. Many surgical teams require parkinsonism to be improved at least 50% on the United Parkinson disease Rating Scale (UPDRS) after the levodopa test to justify surgery. 1 Most patients with PD of 10 to 20 years have off-period motor scores of 40 to 80/108 on the UPDRS. The severity of off-period parkinsonism to justify surgery is highly subjective; however, some groups have arbitrarily set a minimum motor UPDRS score of 30/108. 36 Some reports indicate that in highly select patients, response to levodopa may not predict the potential effectiveness of DBS. STN DBS performed in 2 levodopa-unresponsive tremor-dominant PD patients (with typical F-dopa PET features of PD) had marked improvement of all features of parkinsonism. 42 STN DBS may also be appropriate in selected patients who are unable to tolerate adequate doses of antiparkinson medication because of somnolence, severe nausea, and vomiting despite domperidone and other antiemetics, or psychiatric adverse effects in the absence of cognitive impairment, because this procedure allows marked antiparkinson drug reduction. 43 Patients with parkin mutations (as opposed to "idiopathic PD") have pathology restricted to the substantia nigra and typically have juvenile or young-onset PD. These patients may be the optimal candidates for STN DBS because they maintain an excellent response to levodopa, commonly develop severe levodopa-induced dyskinesias soon after levodopa introduction, and may have a lower incidence of dementia over time. 44 There is very little published data regarding DBS for atypical parkinsonian syndromes. Overall, STN and GPi DBS are ineffective in treating patients with and without levodopa responsive multiple systems atrophy (MSA); although, transient short term benefits may be evident. [45] [46] [47] [48] [49] In highly select patients with MSA, STN and GPi DBS may be appropriate for relief of disabling levodopa induced dyskinesias and dystonia. 36, 50 Currently, there are no reports of DBS in patients with progressive supranuclear palsy (PSP). These preliminary findings do not support DBS as a surgical treatment for patients with atypical parkinsonian syndromes.
A cost-effectiveness analysis indicated that DBS for the treatment of PD may be considered cost effective compared with the best medical treatment, providing that the overall improvement of quality of life is 18% greater than the best medical treatment assessed by a quality-adjusted life year measure. 51 This is indeed the case as bilateral STN DBS results in approximately 50% improvement in off-drug parkinsonism, antiparkinson medication is reduced by approximately 50%, and quality of life is improved by 25%. 52 Furthermore, European estimates indicate that STN DBS for PD has an 80% savings in cost compared with medical treatment alone at 6 months postoperative. 53 It has been hypothesized that surgical interventions targeting the STN might slow the underlying progression of PD. The STN sends glutamatergic projections to the GPi, the SNr, the PPN, and the SNc. Excessive glutamatergic input from the STN could lead to excitotoxic cell death of these targets. 54 If DBS reduces STN firing and neuroprotection can be conclusively demonstrated in humans and not just rodent models of PD, then this intervention may be appropriate in early PD. Furthermore, a recent prospective trial in which 55 Larger studies are warranted to assess the potential therapeutic advantage of DBS earlier in the progression of PD.
Tremor
Thalamic DBS may reduce abnormal rhythmic bursting activity of the stimulated region driven by peripheral and central oscillating loops including deep cerebellar output nuclei. Essential tremor (ET), multiple sclerosis (MS) (causing cerebellar tremor), dystonic tremor, and Holmes or midbrain tremor (usually due to head trauma or brainstem infarction) may all be treated. Although most surgeons target the Vim, stimulation of the ventralis oralis posterior (Vop) and the zona incerta (Zi) may also be effective.
ET is the most common cause of tremor. Approximately 75% of ET patients have disability because of either social embarrassment or tremor-related interference with ADL. ET is characterized by progressively worsening postural and kinetic tremor. Those patients with the most severe kinetic tremor have higher tremor-related disability and are more likely to require surgery. The majority of patients have hand tremor, with coexistent head tremor in 40%, vocal tremor in approximately 20%, and trunk or leg tremor in less than 20% (our observation). Before considering surgery, patients should receive an adequate trial of first line antitremor drugs alone and in combination, including propranolol (240 -360 mg/d) and primidone (300 -750 mg/d). 56, 57 If patients fail first line therapy, trials of second line (clonazepam, alprazolam, and topiramate) and third line (clonidine, acetazolamide, flunarizine, and theophyline) agents may be administered; however, these medications rarely result in marked improvement and surgery should not be unnecessarily delayed to allow trials of these medications. 56 Cerebellar tremor is characterized by action tremor that is less than 5 Hz. Postural tremor may also be present. Typically unilateral or bilateral arm tremor is present, though head and trunk titubation are also common and may be the most disabling form of axial tremor. Superimposed ataxia often makes it difficult to distinguish between disability due to ataxia versus tremor. Deuschl et al have suggested simple inspection of the regularity of movements when patients make typical movements that induce the disability. 58 For example, during examination of a patient attempting to drink from a cup, the examiner must decide if the disability is primarily due to rhythmic or arrhythmic movements. We have found that it is important to examine patients for the presence of marked postural arm tremor (especially by having patients hold their arms in a wing-beating position) because the lack of volitional movement eliminates ataxia as a factor and clarifies that tremor is a significant source of disability especially during feeding and attempting to drink from a cup. Cerebellar tremor is most commonly problematic in patients with MS, after head injury, and occasionally in those with spinocerebellar ataxia or the cerebellar subtype of MSA. Disabling tremor that impairs a patient's quality of life is seen in approximately 10% to 15% of MS clinic patients. 59 Drug therapy with agents such as carbamazepine, clonazepam, L-5-hydroxytryptophan, and buspirone is rarely successful. 59, 60 Occasional patients may have mild improvement with high dose propranolol. 59 Appropriate patients for stereotactic surgery should have tremor that significantly interferes with ADL. MS patients have multiple other nervous system lesions that result in neurologic deficits, and it is important to distinguish between tremor-related disability and disability due to their other deficits. Patients with marked sensory impairment in the target limb, excessive arm weakness (less than grade 4/5), or marked truncal weakness resulting in a bed-bound state should not be offered surgery because significant functional improvement is unlikely to be achieved even if tremor was eliminated. 60 Physiologic assessment in patents with complex tremor and ataxia may help to predict patients most likely to benefit from surgery. Alusi et al determined that thalamotomy resulted in complete ablation of upper extremity postural tremor with frequencies Ͼ3 Hz assessed by an accelerometer, whereas tremor Ͻ3 Hz was not improved postoperatively. 60 Furthermore, frequency analysis during a wrist-tracking task may also be predictive of the response of action tremor to thalamotomy with 80% tremor reduction in those patients with just one frequency peak in the spectra and only 30% tremor reduction in those with multiple frequency peaks. 61 
Dystonia
Dystonia is a highly heterogeneous disorder with both primary (genetically defined and idiopathic) and secondary etiologies, variable distribution (generalized, hemidystonia, segmental, and focal), and variable age of onset. As with PD, surgery for dystonia should be restricted to those patients with significant functional disability despite maximal drug therapy and botulinum toxin injections. Because of this heterogeneity and the relatively small numbers of patients reported in the literature, there are no firm patient selection guidelines. 62 patients with generalized dystonia due to DYT-1 mutations undergoing GPi DBS and genetic testing is warranted preoperatively in all appropriate patients with primary dystonia. 64, 65 Preliminary data suggest that those with secondary dystonia tend to respond more poorly. 66, 67 There has been a shift from targeting the thalamus to the GPi over the past several years; however, there have been no controlled studies evaluating the optimal target for stimulation. There are no predictive clinical tests comparable to levodopa response in PD, and there has been no systematic study of the cognitive effects of surgery for dystonia.
DBS-SURGICAL METHODOLOGY
The operative methodology for DBS is similar to ablative stereotactic neurosurgery, excluding the final stage of electrode implantation. Surgery is usually performed with the patient awake to facilitate feedback as to the beneficial and adverse effects of microstimulation and macrostimulation. Occasionally, surgery is performed under general anesthesia in patients with difficulty tolerating surgery (especially in children and adults with severe dystonia). Antiparkinson and antitremor medication is withheld overnight before surgery so as to maximize tremor and off-period parkinsonism to allow optimal intraoperative assessment of the benefits of stimulation. 36 First, a stereotactic head frame is fixed to the skull to establish a 3D coordinate system to allow correlation of the preoperative imaging with each point in the brain and to prevent intraoperative head movement. Some groups are now performing DBS with frameless stereotaxis. 68 Thereafter CT and/or MRI scanning are performed to identify the anterior and posterior commissures (some groups also perform ventriculography preoperatively for this purpose). Individual thalamic nuclei are not visible with currently available MRI resolution; therefore, indirect targeting using stereotactic arithmetic based coordinates is necessary for thalamic targets. However, the STN and GPi can be seen with MRI allowing direct targeting of these structures. Recently, the use of intraoperative MRI with real time guidance of electrode placement is being explored by some groups.
Microelectrode recording (MER) allows analysis of single neuron firing frequency and discharge patterns including tremor-synchronous discharges and response to movement characteristic of the surgical targets. Microstimulation may also be performed with the same electrode used for MER. There has not been a randomized study of different surgical techniques definitively indicating that MER and microstimulation improves outcomes compared with macrostimulation alone. However, the addition of MER and microstimulation should theoretically improve accuracy of the final electrode implantation site, provide assurance that the electrode is placed in the sensorimotor portion of the GPi or STN, and allow compensation for intraoperative brain shift or imaging anomalies. MER and microstimulation and/or macrostimulation are used to determine the best possible location for the DBS electrode: optimal benefit and a large therapeutic window between beneficial and adverse effects. With both microstimulation and macrostimulation, the medical team assesses the threshold for adverse and beneficial effects (such as improvement in tremor, bradykinesia, and rigidity). Adverse effects due to current spread to adjacent structures are evaluated and include paresthesias, tonic motor contraction, eye deviation, dysarthria, photopsias, and vegetative or affective symptoms (sensations of heat or sweating, depression, or euphoria).
The DBS electrode (Medtronic, Minneapolis, MN) consists of 4 contacts, with each contact 1.5 mm in length and separated by either 0.5 mm (model 3389) or 1.5 mm (model 3387). The hardware is secured to the skull with a plastic cap, metal plate, or cement. The IPG can be implanted the same day as the DBS electrode or in a subsequent surgery. The IPG is implanted under general anesthesia usually in the subclavicular area. Extension cables (Extension Kit 7495) connect the IPG to the DBS electrode and run from the skull, behind the ear and over the mastoid process, and then subcutaneously through the neck (Fig. 1) .
BASIC PRINCIPLES OF DBS PROGRAMMING AND DRUG THERAPY MODIFICATIONS
There are 2 IPGs currently available. The Soletra is a single channel IPG that can be turned off or on by the patient using a magnet (Control Magnet Model 7452) or using a hand-held patient programmer (Access Review 7438). The Kinetra is a dual channel IPG and comes with the Access Therapy Controller, which allows the patient to turn the stimulator off and on as well as modify the stimulation amplitude within parameters specified by the physician. The Kinetra maybe associated with a slightly higher risk of adverse effects such as infection and cutaneous erosion possibly related to its greater weight and size. 69 Because the Kinetra can independently stimulate 2 electrodes, bilateral DBS surgical time may be reduced because only one IPG is inserted subclavicularly compared with the need to implant 2 Soletra devices. 70 Typically, monopolar stimulation is first tested with a single contact on the lead set as the cathode and the pulse generator itself set as the anode. Although generally one contact is used as the cathode, it is occasionally useful to activate 2 adjacent contacts for a broader field of current diffusion. Bipolar stimulation (one electrode contact as the anode and an adjacent electrode as the cathode) is advantageous if adverse effects due to current spread to adjacent structures limits efficacy of stimulation.
Battery consumption for the Kinetra is linear across the entire amplitude range. In contrast, the battery consumption of the Soletra increases abruptly when amplitude is increased from 3.6 to 3.7 V because of a "doubling circuit" in which a
Deep Brain Stimulation second capacitor is switched into the system. Therefore, a stimulation amplitude of Յ3.6 V should be used to prolong battery life when using the Soletra and if greater current spread is required, stimulation pulse width should be increased rather than stimulation amplitude. The Soletra is capable of stimulating at a rate up to 185 Hz and the Kinetra at rates up to 250 Hz. Higher stimulation frequencies increase the "intensity" and effects of stimulation in a given area, and reduce battery life; hence, the lowest frequency of stimulation should be used whenever possible.
Battery life is also dependent on the amount of daily usage. For most PD patients, stimulation is continuous 24 hours per day to maintain nocturnal mobility. However, in ET, the IPG can be turned off at night and battery life is greatly extended. IPG failure with battery end of life (typically 3-7 years for the Soletra) occurs over several days; therefore if patients notice waning of the effects of stimulation, they should contact their physician to have their IPG assessed. Alternatively, battery life can be estimated using cables provided by the manufacture based on stimulation settings and patient daily use, thus allowing prophylactic replacement before the predictive end of life. In PD patients with STN DBS who have substantially decreased their dosage of antiparkinson medication, battery failure may result in severe worsening and theoretical risk of a neuroleptic malignant-like syndrome. Antiparkinson medication may need to be transiently increased until battery replacement. In dystonia, battery drainage could possibly result in acute worsening and life-threatening status dystonicus with rhabdomyolysis. Unlike PD, restarting antidystonia medication is unlikely to be immediately effective and IPG replacement should be performed emergently. For PD or dystonic patients who live in remote areas, battery replacement may be performed prophylactically according to the predicted battery lifetime to prevent these potential complications.
A few DBS programming sessions are usually necessary to optimize the stimulation settings, although the actual number of sessions required may be highly variable between individual patients. If no benefit is attained or significant adverse effects occur with various stimulation parameters with a specific contact, then changing stimulation to a different electrode contact may be beneficial. If no significant benefit is obtained with any contact, then the electrode is likely suboptimally positioned and drug therapy should be increased until the electrode can be surgically repositioned.
Parkinson Disease
Most STN and GPi DBS programming is performed with the patient in the off-state after overnight withdrawal of antiparkinson medication. 71 The effects of STN and GPi DBS on drug-induced dyskinesias should be assessed once the patient has taken more than one dose of levodopa, generally in the afternoon, because dyskinesias commonly exhibit a diurnal pattern.
STN stimulation has a pronounced antiparkinson effect and reduces the threshold for levodopa to induce dyskinesias. STN DBS may itself induce dyskinesias including chorea and dystonia, which may occur immediately or up to 2 days later. As a result, antiparkinson medication must be reduced to reduce dyskinesia. Commonly, medication is gradually reduced and stimulation increased over the first few months postoperatively. Typically, STN stimulation parameters remain relatively stable after 3 months postoperatively with only minor adjustments necessary in subsequent months. Overly aggressive levodopa reduction may result in abulia, apathy, anhedonia, and depression possibly because of withdrawal of its beneficial nonmotor effects in alleviating these symptoms. Depression related to drug withdrawal must be differentiated from that due to inadvertent stimulation of the SNr, which resolves within minutes of stopping stimulation. Although, STN stimulation itself may improve restless leg syndrome (RLS), reduction in dopaminergic medication may unmask RLS symptoms and additional drug treatment may be necessary. 72, 73 Because dopamine agonists and levodopa may induce dyskinesias, benzodiazepines, or opiates may be preferred for treatment of RLS. Vim and GPi DBS generally do not allow for significant medication reduction. 74, 75 GPi DBS has location-specific effects. Stimulation of the ventral GPi suppresses levodopa-induced-dyskinesias and improves rigidity but blocks the beneficial effects of levodopa on bradykinesia and gait. Stimulation of the dorsal globus pallidus (probably GPe) improves bradykinesia and rigidity, but may induce dyskinesias. Hence, stimulation in the middle of the pallidum is the optimal location because this allows one to obtain improvement in parkinsonism and directly suppress dyskinesias. 38, 76 STN DBS in PD has frequency dependent effects on bradykinesia and rigidity with improvements beginning at approximately 100 Hz and plateauing at 130 Hz with only minor additional improvement attainable with higher frequency stimulation. 52, 77, 78 Therefore, STN DBS stimulation of 130 Hz should be used and only increased to 185 Hz if suboptimal benefits are achieved and an increase in pulse width or amplitude results in adverse effects due to current spread. With GPi DBS, most groups use stimulation frequencies of 185 Hz. 76, 79, 80 A pulse width of 60 s is most commonly used for both STN and GPi DBS and occasionally increased to 90 to 120 s.
Tremor
As with STN DBS in PD, Vim DBS for ET has been shown to have frequency dependent effects with marked tremor reduction at 100 to 130 Hz. 81 Stimulation parameters remain fairly stable after 1 month postoperatively with only minor adjustments (such as slightly increasing the amplitude) necessary beyond 3 months. Stimulation parameters and principles of programming are similar to those used in PD:
130 to 185 Hz frequency, 60 to 120 s pulse width, and 1.0 to 3.6 V amplitude. 74, 75, 82, 83 Tolerance to stimulation with reduction of benefit may occur in 10% to 25% of ET patients, particularly those patients with predominantly action tremor. This phenomenon is most likely due to physiological adaptation: stimulation amplitude must be progressively increased over time to maintain benefit, but stopping stimulation for several days (stimulation holiday) resensitizes the system (often only temporarily) and allows good tremor control at a lower stimulation amplitude. 84, 85 Some of these patients have benefited from radiofrequency ablation through the DBS electrode, which eliminated tolerance and reduced tremor. 86 Most patients can keep stimulation off at night, which reduces the likelihood of tolerance developing and increases battery longevity. 87 
Dystonia
Although the optimal stimulation target for different subtypes of dystonia is unknown, the thalamus and the GPi have been used based on the prior positive experience with thalamotomy and pallidotomy. Stimulation settings are widely variable, but most groups have employed frequencies similar to those used in PD. Many groups have found using a very high stimulation pulse width (often with low amplitude) to be particularly beneficial. Unfortunately, this often results in high battery drain necessitating frequent battery replacement. Patients with marked improvement after GPi DBS are often able to discontinue antidystonia medications such as anticholinergics. A response to stimulation may occur within minutes or be delayed and progressive over weeks to months with mobile forms of dystonia tending to respond more quickly than fixed abnormal posturing and gait disorders. As a result, it is recommended to allow at least 24 hours of continuous stimulation on any one setting before further evaluation. Table 2 summarizes the beneficial effects of unilateral and bilateral thalamic DBS in PD patients. On average Vim DBS results in 80% to 90% improvement of contralateral arm tremor and may diminish rigidity but does not improve other features of PD such as bradykinesia and gait disorders. 74, 75 Contralateral levodopa-induced dyskinesias may be improved if the DBS electrode is positioned in the centromedian or parafascicularis nucleus (CM/Pf) or anterior to the Vim ͓the ventralis oralis anterior (Voa)/Vop nucleus͔. Overall, ADL are not improved after thalamic DBS because bradykinesia is generally the greatest source of disability in PD; however, manual tasks worsened by tremor such as handwriting may be improved. 75, 87 The beneficial effects of thalamic stimulation on contralateral tremor are sustained at least 3 years. 74, 75, 88 Unilateral Vim DBS usually does not cause clinically significant worsening of cognition; though on formal neuropsychological testing verbal episodic memory has been found to decline. 89, 90 Common stimulation induced adverse effects include paresthesia, tonic muscle contraction, dysarthria, and disequilibrium, which resolve with terminating stimulation or adjusting stimulation parameters. 15, 87, 88 Current spread ventrally to cerebellothalamic fibers may also result in stimulation-induced ataxia. 91 Bilateral stimulation more commonly causes adverse effects, especially dysarthria, dysequilibrium, and gait disorders. Table 2 summarizes the overall motor effects of unilateral and bilateral GPi and STN DBS. It has been demonstrated that STN DBS is superior at improving quality of life and motor function than best medical treatment at 6 months; however, DBS did carry a greater risk of adverse effects. 52 GPi and STN DBS demonstrate similar beneficial effects with improvement of tremor and rigidity occurring almost immediately, whereas other parkinsonian symptoms improve over several minutes for GPi DBS and may continue to improve over several hours for STN DBS.
CLINICAL RESULTS
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GPi and STN DBS
Bilateral GPi and STN DBS both markedly improve off-period motor UPDRS and off-drug ADL scores 6 to 12 months postoperatively. 69 On-drug UPDRS motor scores and on-drug ADL scores are modestly improved likely because of reduction in interfering dyskinesias. 93 Some groups report that with STN DBS, approximately 10% of all patients are able to stop all drug therapy at 1 to 2 years postoperatively. 94 Furthermore, with STN DBS, levodopa-induced dyskinesias are also significantly improved because of reduction of antiparkinson medication, whereas GPi DBS directly suppresses dyskinesias. 23, 91, 95 Long-term reports of bilateral STN DBS indicate that patients remain considerably improved 5 years postoperatively compared with baseline. Off-drug motor and ADL scores deteriorated over 5 years of treatment but remained much better than baseline and antiparkinson medication requirements also continued to be significantly reduced. By 3 to 5 years postoperatively on-drug motor and ADL scores became comparable or worse than baseline, largely reflecting progression of levodopa and stimulation-refractory axial features of parkinsonism including gait, postural reflexes, and speech. 21, 96 Limited long-term GPi DBS data at 4 years postoperative suggests similar outcomes as STN DBS; although, no significant decrease of levodopa dosage is evident. 97 However, some case series suggest a significant deterioration after 1 to 3 years with worsening of motor fluctuations and disability requiring more aggressive drug therapy. 98, 99 Some of these patients have subsequently undergone bilateral STN DBS with significant improvement. 29 PD-associated camptocormia is characterized by marked flexion of the trunk and often responds poorly to medical treatment. However, several patients have also reported sustained improvement of PD-associated camptocormia with bilateral GPi and STN DBS.
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Although there have not been any large published randomized studies comparing GPi and STN DBS, some data suggest that STN DBS may be superior. As mentioned above, STN DBS allows marked reduction or discontinuation of antiparkinson medication, which is largely unchanged with GPi DBS. Furthermore, STN stimulation requires less battery power because of lower stimulation parameters probably because the STN is a smaller target compared with the pallidum. 80, 103 This results in fewer surgeries to replace the battery and, as a result, less cost. The STN may be an easier surgical target because it is more clearly identified by MRI. Despite these advantages compared with GPi DBS, STN DBS requires more frequent follow-up visits with complex postoperative management of medication and stimulation induced adverse effects. 103 Nonmotor fluctuations (NMF) have also been reported to improve after STN DBS with the most notable improvements in asthenia, irritability, and drenching sweats. 104 In addition, improved quality and increased total sleep time as well as decreased daytime sleepiness (likely due to increased nocturnal mobility) have been reported. 105, 106 Select patients with highly asymmetric parkinsonism may be candidates for unilateral STN DBS; although this surgery should be undertaken with some caution because the need to reduce antiparkinson medication may lead to a lopsided effect with the ipsilateral side of the body being undertreated and becoming excessively parkinsonian. Nevertheless, in very asymmetric tremor-dominant patients, we have been able to successfully apply this intervention without problems. 42 The Rush group also reported a cohort of 23 patients with advanced PD with a median 31% improvement in off-drug motor UPDRS scores 4 months postoperatively.
Few patients were deemed to require contralateral STN DBS. 107 Furthermore, there is preliminary evidence that ipsilateral symptoms also may be improved; although, not as significantly compared with contralateral symptoms. 27 The majority of adverse effects of bilateral GPi and STN DBS are transient, occurring as the stimulation parameters are adjusted. Stimulation-induced adverse effects with GPi DBS include paresthesias and tonic motor contraction due to internal capsule stimulation, and nausea and phosphenes with stimulation of the optic tract. 79, 93, 98 Bilateral GPi DBS has been reported to be cognitively well-tolerated, though lexical fluency may be reduced. Acute STN stimulation (eg, during intraoperative targeting and adjustment of stimulation parameters) induces reversible dyskinesias (chorea, dystonia, and ballism) in most patients with optimally placed electrodes and pretarsal blepharospasm (often requiring treatment with botulinum toxin injection) in 10% to 20% of patients. A variety of transient stimulation-induced adverse effects with STN DBS are dependent on the exact electrode location, including dysarthria, tonic contraction, paresthesias, and diplopia. 71, 93 In younger cognitively intact patients, STN DBS is extremely well-tolerated and may actually improve working memory though it can slightly impair lexical fluency. However, in older patients (especially those with borderline cognitive function) a number of cognitive processes reliant on intact frontal-striatal circuitry may be significantly impaired resulting in (in the worst cases) a mental state comparable to progressive supranuclear palsy (PSP). 20, 108 In elderly patients, transient confusion can persist for up to 2 weeks postoperatively and is usually easily managed. In rare cases, confusion accompanied by psychotic features such as hallucinations can occur and the use of atypical neuroleptics such as clozapine may be useful.
GPi DBS is complicated by neuropsychiatric symptoms less frequently than STN DBS; however, there are no large blinded multicenter studies utilizing standardized assessment tools to verify these preliminary findings. 109 As mentioned above, apathy, anhedonia, abulia, and fatigue may occur with excessive levodopa reduction during STN DBS. 107, 108, 110 Depression also may occur because of inadvertent current spread to the SNr or reduction of levodopa dose. 111 STN DBS may also increase the risk of suicide even in patients with optimal motor outcome. 112, 113 STN stimulation also may induce mania including hypersexuality (possibly due to stimulation or microablation effects); however, symptoms gradually subside several months post onset. 114 -116 Mirthful laughter, which subsides immediately upon termination of stimulation, has also been elicited most likely because of stimulation of the limbic potion of the STN (the medial tip). 117 In addition a few case reports indicate postoperative abuse of levodopa for euphoric effects with STN DBS. 21, 108 Finally, marked benefit on comorbid obsessive-compulsive disorder (OCD) in PD patients has also been achieved with STN DBS. 118, 119 The variety of psychiatric effects observed with STN DBS emphasizes the important nonmotor role of the basal ganglia.
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Tremor
In ET, unilateral Vim DBS results in 80% to 100% reduction in contralateral arm postural and action tremor that is sustained at least 3 years and possibly as long as 7 years postoperatively. 74, 81, 84, 85, 120, 121 Although unilateral stimulation results in some improvement in head and vocal tremor, greater improvement (30%-50%) is noted with bilateral DBS. 75, 122 In addition, antitremor medication can be markedly reduced or eliminated. 121 Transient stimulation induced adverse effects are commonly seen and are to identical to Vim DBS for PD. 81, 83, 120 Similarly, bilateral procedures are associated with a heightened risk of adverse effects, especially dysarthria and dysequilibrium. 83, 87 There have been several recent studies of Vim DBS for MS-associated cerebellar tremor. Although several studies have reported no or very limited benefit, others utilizing very careful patient selection (differentiating between ataxia that does not alleviate with DBS and tremor) have reported improvement in contralateral upper limb action tremor. 123 However, the effectiveness of Vim DBS on tremor may decrease over the first year postoperatively in 16% to 25% of patients with MS. 124 Improvements in ADL are even less consistent, which most likely reflects the presence of other MS-related neurologic deficits. [125] [126] [127] Such patients also have an increased risk of adverse effects due to the presence of multiple coexistent brain lesions and theoretically, a possible negative effect on disease progression including postoperative exacerbation of MS due to breach of the blood/brain barrier. 60 There are no reports on the long-term beneficial and adverse effects of this therapy.
Dystonia
Thalamic DBS
There is limited data reported on thalamic DBS for dystonia. In one small series of patients with either primary or secondary dystonia, Vim DBS resulted in mild to moderate improvement in only 50% of patients. 66 There is increasing evidence that the GPi may be a better target in dystonia as some patients with poor benefit from Vim DBS have received much greater benefit with GPi stimulation. 67 Furthermore, a patient with severe tardive dystonia who underwent bilateral simultaneous implantation into GPi and Vim obtained benefit from GPi DBS but no additional improvement with concurrent Vim stimulation. 128 Although GPi DBS seems to be the most promising surgical treatment for dystonia, further studies are warranted to investigate other surgical targets because GPi surgery is not effective in all dystonic patients, especially those with secondary dystonia.
GPi DBS
In open label studies, patients with Torsin A gene (DYT-1) mutations demonstrate 50% to 80% improvement in motor and ADL scores, whereas non-DYT-1 primary generalized dystonic patients have less significant benefit with similar scores improved 40% to 70%. 129 -131 Patients with long-standing dystonia can have similar improvement from GPi DBS compared with patients who have a much shorter duration of the disease. 131 Furthermore, improvement in longstanding orthopedic deformities can be seen after longterm stimulation. 66 Recently, Kupsch et al performed a 3-month randomized double-blinded sham stimulation controlled study in which a total of 40 patients with primary generalized or segmental dystona received bilateral GPi DBS. The stimulation group had a 39% reduction in motor scores and a 30% improvement in quality of life scores, whereas the sham stimulation group did not demonstrate significant differences in motor scores or quality of life assessments. 130 There are increasing reports of significant improvement after GPi DBS in patients with secondary dystonia without focal brain lesions (eg, postanoxic states) although lesser improvements compared with primary dystonia. 63, 64, 66, 132, 133 A patient with postanoxic generalized dystonia underwent bilateral GPi DBS, which resulted in only minimal benefit. This patient subsequently had the DBS electrodes relocated to the Voa, and 4 months postoperatively the patient significantly improved. 134 The presence of an abnormal MRI scan has been reported to reduce the likelihood of a good response in patients with secondary dystonia. 64, 67 Nevertheless, a mixed cohort of patients with various causes of dystonia demonstrated a 32% improvement in dystonic symptoms 1 year postoperatively with sustained efficacy at 3-year followup. Reports also suggest that GPi DBS may be an effective treatment in individuals with metabolic diseases such as pantothenate kinase-2 mutation (Hallervorden Spatz syndrome) and glutaric acidemia, although preliminary results have been highly variable. 63, 135 
ADDITIONAL APPLICATIONS OF DBS
Pain
DBS for chronic pain has been used for more than 25 years; however, because of advances in surgical and nonsurgical treatments its use has substantially decreased. Despite these advancements in the treatment of pain, DBS continues to be a surgical option when conventional therapies fail. There are 2 main categories of pain: nociceptive-characterized by diffuse midline deep pain due to discharge of peripheral pain receptors (nociceptors) in response to tissue damage that may or may not be associated with damage to the nervous system, and neuropathic-characterized by unilateral localized, burning surface pain caused by central or peripheral nervous system injury unrelated to other tissue damage. 136, 137 Traditionally, the site of implantation for nociceptic pain has been the periventricular/periaqueductal gray matter (PVG), and for neuropathic pain surgeons have targeted the sensory thalamic nuclei. Furthermore, optimal stimulation settings are highly dependent on the site of electrode implantation such that low voltage, low frequency (50 -100 Hz), and narrow pulse widths are most effective with PVG stimulation whereas high voltage, high frequency, and wider pulse widths are effective with sensory thalamic stimulation. 136, 138 Approximately 60% of patients with various forms of pain report significant long-term pain relief with DBS. 136 Tolerance may occur in 10% to 20% of patients and it is possible that the long-term benefits may decline over time. 136, 139 The Neurologist • Volume 13, Number 5, September 2007
Deep Brain Stimulation
Recently, 2 reports evaluated the use of DBS implanted into the PVG and ventroposterolateral thalamic nucleus in patients with poststroke chronic neuropathic pain. 140, 141 On average 70% of patients obtained pain relief with an average of 40% to 50% reduction of neuropathic pain. Interestingly, most of patients obtained pain relief with low frequency stimulation (5-35 Hz) of the PVG alone.
DBS for the treatment of phantom limb pain has also been recently evaluated. 142 Bittar et al, performed PVG and thalamic stimulation in 3 patients with phantom limb-associated pain. Pain was alleviated in all patients with an average reduction of 62% at a mean follow-up of 13 months. Furthermore, in 2 patients, opiate intake was also reduced. 143 Trigeminal autonomic cephalalgias (TAC) include cluster headache, paroxysmal hemicrania, and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT). The posterior inferior hypothalamic gray matter is proposed to be the origin of TAC and DBS may be an appropriate treatment in patients who do not obtain benefit from medication or trigeminal nerve section. 144 Leone et al recently reported marked improvement with hypothalamic DBS in 13 of 16 patients with cluster headache with a mean follow-up of 23 months. Furthermore, symptoms returned in all 13 patients with stimulation off. 145 Hypothalamic DBS has also been performed in a single patient with medication resistant SUNCT who obtained marked benefit.
146
Epilepsy
Many patients have poorly controlled epilepsy despite optimal medical therapy and are not candidates for conventional surgery such as temporal lobectomy. Currently, vagal nerve stimulation (VNS) is offered to many such patients; VNS efficacy is modest at best with a relatively small proportion of patients becoming seizure-free or able to withdraw from drug therapy. Stimulation of the STN and thalamic nuclei has been investigated in this same difficult to treat population. In one model of epilepsy, the SNr sends inhibitory neurons to the dorsal midbrain anticonvulsant zone (DMAZ), which inhibits the cortex; seizures occur when DMAZ inhibition of the cortex is decreased. It has been proposed that STN DBS may reduce SNr inhibition of the DMAZ, and return DMAZ cortical inhibition to normal levels. 147 Chabardès et al reported preliminary data on the effectiveness of STN DBS for epilepsy in 5 patients (4 who received bilateral and 1 received unilateral DBS electrode implantation) with a mean follow-up of 20.5 months in 4 of them. This cohort of 4 patients had a 64% reduction in seizure frequency and 2 patients were able to completely stop drug therapy. 148 Additional case reports indicate similar results in reduction of seizure frequency as well as decreased severity of seizures. 149 The best responders had partial seizures arising from the sensorimotor cortex; hence, success of this treatment may correlate with seizure subtype.
Stimulation of the anterior nucleus (AN) and the centromedian nucleus (CM) of the thalamus may also be effective for seizure control, possibly related to blocking excitatory synchronized thalamocortical input. 150 Bilateral DBS of the AN may reduce seizure frequency by 45% to 54% per month with sustained improvement greater than 12 months. 151, 152 Velasco et al reported a mean reduction in seizure frequency of 73% in 13 patients with bilateral CM DBS evaluated at least 1-year postoperatively (mean evaluation 41 months). 153 There is some evidence that improvement of seizures with DBS into the AN may be due to a microablation effect, because several patients report improvement despite absence of stimulation for 1 month. 154 However, long-term benefits may be due to continuous stimulation and additional research is required to validate these findings. Reports also suggest that amygdalohippocampal DBS may be effective in patients with temporal lobe seizures who might otherwise be treated with conventional temporal lobectomy.
155-157
Neuropsychiatric Disorders
Specific guidelines to select patients with Gilles de la Tourette syndrome for DBS have recently been published. 158, 159 There are several case reports suggesting that stimulation of midline thalamic nuclei or GPi may be effective in markedly reducing medication-refractory tics. 160, 161 On average, tic severity and frequency is improved 50% to 90% in select patients. [162] [163] [164] [165] Ablative surgery for OCD has been performed for many years with reasonable efficacy in appropriately selected medication-refractory patients. DBS of the anterior limb of the internal capsule (one of the main targets for ablation) has been reported in several case series. 166, 167 Recently, 2 studies evaluating the benefits up to 3 years postoperatively found sustained improvement in behavioral symptoms and assessments of functionality, which allowed patients to live independently. 168, 169 Furthermore, in these patients, medication was markedly reduced. 168 However, a select number of patients did not respond to DBS. Overall, DBS is well tolerated; although, battery life may be quite short and psychiatric adverse effects including transient hypomania may be seen. 168 These findings suggest that in otherwise highly selected patients, DBS may improve chronic OCD.
Depression is a common disorder causing severe morbidity. In medication-refractory patients, DBS may be a viable treatment option. The subgenual cingulate white matter is currently targeted for DBS as this region is metabolically overactive in treatment-resistant depression and has wide connections with areas that can manifest the symptoms of depression. 170 Lozano's group performed bilateral subgenual cingulate white matter tract DBS in 6 patients with treatment-resistant depression. At 6 months post operatively, 4 patients obtained marked beneficial effects and 3 of these patients were considered to be in remission. Interestingly, the change in pattern of cerebral activity assessed with PET was comparable to changes seen in previous studies in which patients were treated effectively with medication. 170 Additionally, some groups have begun to target the nucleus accumbens predominately to alleviate anhedonia. 171 Franzini et al recently described 2 patients with low IQs concurrent with disruptive and aggressive behavior, which was resistant to medication and behavioral therapy. Based on similar cases successfully treated with ablative procedures, the posteromedial hypothalamus was selected for implantation of the DBS electrodes. One year postoperatively, both
Kern and Kumar
The Neurologist • Volume 13, Number 5, September 2007 patients obtained improvement in their behavior. 172 In contrast, a single case report indicated that aggressive behavior may be induced by stimulation of this region. 173 It will be important to consider the ethical issues of such behavioraltering surgery (including patients' consent) as such cases of DBS become widespread.
FUTURE DEVELOPMENTS
New applications of DBS are currently being investigated including obesity, choreothetosis associated with Huntington chorea, and in the vegetative state. Hardware manufacturers have developed rechargeable IPG, which may eliminate the need for battery replacement. The development of a closed loop system with sensors that detect local neuronal activity, a processing system to interpret this data, and potentially multiple output electrodes might allow more precise and physiologic modification of the activity of local nuclei and downstream connections, resulting in greater efficacy and applicability of DBS to a greater variety of neurologic disorders. These technological advances could move DBS to a first line therapy. Finally, the cost of equipment and duration of surgery may be able to be significantly lowered, allowing greater availability of this surgical treatment.
